The epidermal growth factor receptor (EGFR) overexpressed in many epithelial tumors is an attractive target for tumor therapy since numerous blocking agents of EGFR signaling have proven their anti-tumor activity. A novel monoclonal antibody (mAb), A13, was generated from mice immunized with human cervical carcinoma A431 cells. In addition to binding to soluble EGFR with affinity of ~5.8 nM, the A13 mAb specifically bound to a variety of tumor cells expressing EGFR. A13 mAb efficiently inhibited both EGF & transforming growth factor (TGF)-α dependant EGFR tyrosine phosphorylation in cervical and breast tumor cells and also in vitro colony formation of EGFR-overexpressing lung tumors. Competition and sandwich ELISAs, competitive surface plasmon resonance, and domain-level epitope mapping analyses demonstrated that mAb A13 competitively bound to the domain III (amino acids 302-503) of EGFR with EGF, but recognized distinct epitopes from those of cetuximab (Erbitux®). Human monoclonal antibodies selected from a human antibody library based on the A13 mAb reflected the biochemical properties of A13 mAb and one of them, ER2, is being developed for cancer therapeutics.
저자
Se-Ho Kim [ Antibody Engineering Lab., Research Center, Green Cross Corp., 303, Bojeong-dong, Giheung-gu, Yongin, 446-770, Korea. ]
한국생물공학회 [The Korean Society for Biotechnology and Bioengineering]
설립연도
1984
분야
공학>생물공학
소개
이 법인은 생물 공학의 발전과 보급에 이바지하고, 회원 상호 간의 연구 협력과 친목을 도모함을 목적으로 한다
1. 생물공학 분야의 발전을 위한 연구 협력
2. 생물공학의 실용화를 촉진시키기 위한 산학 협동
3. 학술연구 발표회, 강연회, 연수회 등 학술활동의 개최
4. 국,영문 학술지,소식지,학술회의 Proceedings 및 학술도서의 발간
5. 생물공학 발전을 위한 정책 건의
6. 기타 국제 교류 등 본 학회의 목적 달성을 위한 제반 활동